Results 111 to 120 of about 41,281 (176)

Based a machine learning approach to investigate the factors influencing nirmatrelvir/ritonavir exposure in human plasma: a multicenter, observational study. [PDF]

Front Cell Infect Microbiol
Zhang Y, Yang X, Sun L, Zhang R, Fan W, Lin N, Lin B.   +6 more
europepmc   +1 more source

Combined antiretroviral therapy with low- or normal-protein, high-calorie diets appears to induce significant deleterious electrocardiographic changes in a rodent model. [PDF]

Braz J Med Biol Res
Chege BM, Mwangi PW, Githinji CG, Bukachi F.   +3 more
europepmc   +1 more source

Predictive modeling of influenza strain drugs using temperature-based topological indices and regression analysis via multi-criteria decision making techniques. [PDF]

Sci Rep
Hayat H, Ahmad S, Siddiqui MK, Petros FB.   +3 more
europepmc   +1 more source

Antivirals Targeting Coronavirus RNA-Dependent RNA Polymerase and Main Protease: From Mechanisms of Action to Outcomes in COVID-19 Clinical Trials. [PDF]

Microb Biotechnol
Brüssow H.
europepmc   +1 more source

Nirmatrelvir/Ritonavir-Induced Calcium Channel Blocker Intoxication Successfully Treated by High Dose Insulin Therapy. [PDF]

Acta Cardiol Sin
Chen CY, Cia CT.
europepmc   +1 more source

Safety and Efficacy of Concomitant Nirmatrelvir/Ritonavir and Direct Oral Anticoagulant Therapies for COVID-19 Among Patients With Atrial Fibrillation. [PDF]

J Am Heart Assoc
Wong CK, So BY, Leung IS, Choo A, Chiu HAC, Tam FC, Lin M, Kwok WC, Lam SC, Chan KE, Un KC, Lam TH, Chu WM, Tam AR, Hung FN, Lip GYH, Tse HF.   +16 more
europepmc   +1 more source

Patterns of use of oral antivirals for COVID-19 in people 70 years and over in Victoria, Australia: a linked data study. [PDF]

BMC Infect Dis
Edwards LJ, Scaria A, Cheng AC, Amin J, Robinson EJ, Sumpton C, Liu B.   +6 more
europepmc   +1 more source

COVID-19 Rebound in Nirmatrelvir Plus Ritonavir Treatment and Control Groups: Prospective Cohort Study. [PDF]

Interact J Med Res
Kueper JK, Kottilil K, Quer G, Chiang DC, Spencer EG, Purushotham J, Ramos E, Roumani L, Andersen KG, Topol EJ, Pandit JA, Mina MJ.   +11 more
europepmc   +1 more source

Development of an adult whole-body PBPK model of irinotecan and its metabolites for predicting UGT1A1/CYP3A-mediated drug-drug interactions. [PDF]

Front Pharmacol
Chen B, Li L, Xu W, Xu H, Zhu X, He Q, Zhu X, Chi-Lui Ho P, Xiang X, Ji P.   +9 more
europepmc   +1 more source

Real-world untreated risk of hospitalization and death in a nirmatrelvir/ritonavir treatment-eligible population with mild-to-moderate COVID-19 in the United States: a systematic literature review. [PDF]

BMC Infect Dis
Migliaccio-Walle K, Mugwagwa T, Cha-Silva AS, Gong CL, Campbell D, Quercia R, Bergroth T, Veenstra DL, Moran MM, Dzingina M.   +9 more
europepmc   +1 more source